MARKET

LRMR

LRMR

Larimar Therapeutics Inc
NASDAQ
12.12
+0.42
+3.59%
Closed 19:27 02/23 EST
OPEN
11.77
PREV CLOSE
11.70
HIGH
12.50
LOW
11.75
VOLUME
523.02K
TURNOVER
0
52 WEEK HIGH
13.68
52 WEEK LOW
2.180
MARKET CAP
740.15M
P/E (TTM)
-15.9579
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LRMR last week (0219-0223)?
Weekly Report · 54m ago
Buy Rating Affirmed: Larimar Therapeutics’ Nomlabofusp Shows Potential in Friedreich’s Ataxia Treatment
TipRanks · 5d ago
Over $37M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
U.S. Stocks closed lower on Friday but there were a few notable insider trades. Hawthorn Bancshares, Inc. And Alteryx made notable insider purchases. When insiders purchase shares, it indicates confidence in the company's prospects or that they view the stock as a bargain.
Benzinga · 6d ago
Weekly Report: what happened at LRMR last week (0212-0216)?
Weekly Report · 02/19 12:30
Insider Trading: Larimar’s (NASDAQ:LRMR) Director Makes an Enormous Purchase
One of Larimar Therapeutics’ directors and more-than-10% owners, James E. Flynn, disclosed an enormous purchase of the company’s shares, worth about $37.5 million. LRMR is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The stock has gained 307% in the past three months.
TipRanks · 02/19 07:08
Larimar Therapeutics Secures $161.8M from Public Offering
TipRanks · 02/16 21:27
Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Shares of Cisco Systems, Inc. Fell in today’s pre-market trading following second-quarter results. The company announced a restructuring plan to cut approximately 5% of its global workforce. The Dow futures were trading higher by around 70 points on Thursday morning. Nu Skin Enterprises and Herbalife were among the big stocks recording losses in today's trading.
Benzinga · 02/15 10:30
Larimar Therapeutics Inc: Statement of acquisition of beneficial ownership by individuals
Press release · 02/15 06:27
More
About LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its cell penetrating peptide (CPP) technology platform. The Company’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreichs ataxia (FA). CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with FA. FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient frataxin (FXN) due to a genetic abnormality. It also focuses on using its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. Its CPP platform enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets.

Webull offers Larimar Therapeutics Inc stock information, including NASDAQ: LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.